CSBR (Champions Oncology) ROCE %: -9.47% (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.14
GF Value $6.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology ROCE %?

Champions Oncology CSBR 64 ROCE % is -9.47% as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Champions Oncology's annualized ROCE % for the quarter that ended in Jan. 2026 was -9.47%.

Champions Oncology  (NAS:CSBR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Champions Oncology ROCE % Related Terms

Champions Oncology ROCE % Historical Data

* Premium members only.

The historical data trend for Champions Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology ROCE % Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 3.54 -29.20 -80.62 74.09

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 210.04 -71.24 -24.82 9.33 -9.47
CSBR
64GF Score
Champions Oncology Inc CSBR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology ROCE % Calculation

Champions Oncology's annualized ROCE % for the fiscal year that ended in Apr. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=4.846/( ( (26.132 - 21.541) + (32.344 - 23.853) )/ 2 )
=4.846/( (4.591+8.491)/ 2 )
=4.846/6.541
=74.09 %

Champions Oncology's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-0.748/( ( (30.162 - 22.141) + (28.447 - 20.677) )/ 2 )
=-0.748/( ( 8.021 + 7.77 )/ 2 )
=-0.748/7.8955
=-9.47 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -9.47% mean?
Champions Oncology (CSBR) has a ROCE % of -9.47% as of Jan. 2026.
Is Champions Oncology's ROCE % too high?
Champions Oncology's current ROCE % is -9.47%. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's ROCE % compare to ANVS and HYFT?
Champions Oncology's ROCE % of -9.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Champions Oncology's current ROCE % is -9.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.14 — trading 7.3% below its estimated fair value. The current ROCE % is -9.47%. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Champions Oncology (CSBR), the current ROCE % is -9.47% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.14 is trading 7.3% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • ROCE %: -9.47%
  • GF Value™: $6.62 vs. price of $6.14 (7.3% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.14
Price
$6.62
GF Value